89 related articles for article (PubMed ID: 18760830)
1. Phase 1 study of human plasma-derived plasmin (TAL-05-00018) in hemodialysis graft occlusion.
Shlansky-Goldberg R
Thromb Res; 2008; 122 Suppl 3():S16-9. PubMed ID: 18760830
[TBL] [Abstract][Full Text] [Related]
2. A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion.
Shlansky-Goldberg RD; Matsumoto AH; Baumbach GA; Siegel JB; Raabe RD; Murphy TP; Deng C; Ray Dawkins J; Marder VJ
J Thromb Haemost; 2008 Jun; 6(6):944-50. PubMed ID: 18384651
[TBL] [Abstract][Full Text] [Related]
3. Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results.
Marder VJ; Comerota AJ; Shlansky-Goldberg RD; Davis JP; Deng C; Hanna K; Fineberg D
J Thromb Haemost; 2012 Jun; 10(6):985-91. PubMed ID: 22487025
[TBL] [Abstract][Full Text] [Related]
4. Development of catheter-directed intrathrombus thrombolysis with plasmin for the treatment of acute lower extremity arterial occlusion.
Comerota AJ
Thromb Res; 2008; 122 Suppl 3():S20-6. PubMed ID: 18701142
[TBL] [Abstract][Full Text] [Related]
5. Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis.
Hoefer IE; Stroes ES; Pasterkamp G; Levi MM; Reekers JA; Verhagen HJ; Meijers JC; Humphries JE; Rotmans JI
J Vasc Interv Radiol; 2009 Jul; 20(7):951-8. PubMed ID: 19481472
[TBL] [Abstract][Full Text] [Related]
6. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
[TBL] [Abstract][Full Text] [Related]
7. Cross-species pharmacologic evaluation of plasmin as a direct-acting thrombolytic agent: ex vivo evaluation for large animal model development.
Landskroner K; Olson N; Jesmok G
J Vasc Interv Radiol; 2005 Mar; 16(3):369-77. PubMed ID: 15758133
[TBL] [Abstract][Full Text] [Related]
8. Structure and activity of plasmin and other direct thrombolytic agents.
Novokhatny V
Thromb Res; 2008; 122 Suppl 3():S3-8. PubMed ID: 18718639
[TBL] [Abstract][Full Text] [Related]
9. Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
Novokhatny VV; Jesmok GJ; Landskroner KA; Marder VJ; Zimmerman TP
Trends Pharmacol Sci; 2004 Feb; 25(2):72-5. PubMed ID: 15102492
[TBL] [Abstract][Full Text] [Related]
10. Tissue plasminogen activator as a hemodialysis catheter locking solution.
McGill RL; Spero JA; Sysak JC; Sandroni SE; Marcus RJ
Hemodial Int; 2008 Jul; 12(3):348-51. PubMed ID: 18638092
[TBL] [Abstract][Full Text] [Related]
11. Thrombolytic therapy for deep vein thrombosis: potential application of plasmin.
Marder VJ
Thromb Res; 2009; 123 Suppl 4():S56-61. PubMed ID: 19303506
[TBL] [Abstract][Full Text] [Related]
12. Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin.
Hunt JA; Petteway SR; Scuderi P; Novokhatny V
Thromb Haemost; 2008 Sep; 100(3):413-9. PubMed ID: 18766256
[TBL] [Abstract][Full Text] [Related]
13. Thrombolysis with plasmin: implications for stroke treatment.
Marder VJ; Jahan R; Gruber T; Goyal A; Arora V
Stroke; 2010 Oct; 41(10 Suppl):S45-9. PubMed ID: 20876504
[TBL] [Abstract][Full Text] [Related]
14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
15. Urokinase: new indication. Thrombosed venous and dialysis catheters: when heparin fails. Urokinase clears about 75% of thrombosed venous catheters intended for long-term use with a dose-related increase in the bleeding risk.
Prescrire Int; 2009 Jun; 18(101):118. PubMed ID: 19637430
[No Abstract] [Full Text] [Related]
16. Pre-clinical studies of plasmin: superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator.
Marder VJ
Thromb Res; 2008; 122 Suppl 3(Suppl 3):S9-S15. PubMed ID: 18722003
[TBL] [Abstract][Full Text] [Related]
17. Thrombolysis for intravascular thrombosis in neonates and children.
Raffini L
Curr Opin Pediatr; 2009 Feb; 21(1):9-14. PubMed ID: 19242237
[TBL] [Abstract][Full Text] [Related]
18. [The action of modified plasmin on the lysis of experimental thrombi].
Kizim AI; Pokrovskaia TN
Vrach Delo; 1990 May; (5):39-40. PubMed ID: 1697714
[No Abstract] [Full Text] [Related]
19. Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial.
Lee YK; Koo JR; Kim JK; Park II; Joo MH; Yoon JW; Noh JW; Vaziri ND
Am J Kidney Dis; 2009 May; 53(5):815-22. PubMed ID: 19324483
[TBL] [Abstract][Full Text] [Related]
20. Endovascular treatment of stenosis of autogenous arteriovenous access for hemodialysis.
Kipiani VK; Parkosadze GL; Gogorishvili IR; Urushadze OP; Kipiani KB; Kipshidze NN
Georgian Med News; 2009 Jan; (166):13-7. PubMed ID: 19202210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
